Blood neurofilament light concentration at admittance: a potential prognostic marker in COVID-19.

Like Comment
To test the hypotheses that blood biomarkers for nervous system injury, serum concentrations of neurofilament light chain protein (NfL) and glial fibrillary acidic protein (GFAp) can serve as biomarkers for disease severity in COVID-19 patients.Forty-seven inpatients with confirmed COVID-19 had blood samples drawn on admission for assessing serum biomarkers of CNS injury by Single molecule array (Simoa), NfL and GFAp. Concentrations of NfL and GFAp were analyzed in relation to symptoms, clinical signs, inflammatory biomarkers and clinical outcomes. We used multivariate linear models to test for differences in biomarker concentrations in the subgroups, accounting for confounding effects.In total, 21% (n = 10) of the patients were admitted to an intensive care unit, and the overall mortality rate was 13% (n = 6). Non-survivors had higher serum concentrations of NfL (p 

View the full article @ Journal of neurology

Get PDF with LibKey
Authors: Anne Hege Aamodt, Einar August Høgestøl, Trine Haug Popperud, Jan Cato Holter, Anne Ma Dyrhol-Riise, Kristian Tonby, Birgitte Stiksrud, Else Quist-Paulsen, Tone Berge, Andreas Barratt-Due, Pål Aukrust, Lars Heggelund, Kaj Blennow, Henrik Zetterberg, Hanne Flinstad Harbo


The wider, wiser view for healthcare professionals. ClinOwl signposts the latest clinical content from over 100 leading medical journals.
6577 Contributions
0 Following